Department of Dermatology, University Hospital Bern, Inselspital, University of Bern, Switzerland.
Swiss Med Wkly. 2010 Jul 15;140:w13036. doi: 10.4414/smw.2010.13036. eCollection 2010.
BACKGROUND/AIMS: Skin tumours, in particular squamous-cell carcinomas (SCC), are the most common malignant conditions developing in transplant recipients. The aim of this study is to investigate the frequency and type of skin cancer in patients receiving immunosuppressive therapy after organ transplantation.
Multivariate logistic regression analysis was performed on data of 243 renal transplant patients who attended the dermatology outpatient clinic for the first time after transplantation in the period January 2002-October 2005.
We found an increased risk of actinic keratosis (AK) and SCC in renal transplant recipients with a basal cell carcinoma (BCC) / SCC ratio of 1:7. Older patients had AK more frequently (odds ratio [OR] 1.11, 95% confidence interval [CI] 1.06-1.15; p <0.0001) and SCC (OR 1.14, CI 1.07-1.22; p <0.0001) than younger patients. Men had AK (OR 0.19, CI 0.08-0.45; p = 0.0002) and SCC (OR 0.25, CI 0.07-0.89; p = 0.0332) more frequently than women. The duration of immunosuppressive therapy correlated significantly with the numbers of AKs (OR 1.15, CI 1.08-1.24; p <0.0001) and SCCs (OR 1.16, CI 1.05-1.28; p = 0.0025), and patients with fair skin had more AKs (OR 0.31, CI 0.14-1.24; p <0.0001) and SCCs (OR 0.11, CI 0.02-0.52; p = 0.0054) than darker skinned patients. We could not identify any specific immunosuppressive drug as a distinct risk factor for AK or non-melanoma skin cancer (NMSC).
Skin cancers are increased in the renal transplant population. Main risk factors for skin cancers are fair skin type and long duration of immunosuppressive therapy. A follow-up programme is necessary for early detection of skin cancer and precancerous conditions. Preventive strategies should include specialist dermatological monitoring and self-examination.
背景/目的:皮肤肿瘤,尤其是鳞状细胞癌(SCC),是移植受者中最常见的恶性疾病。本研究的目的是调查器官移植后接受免疫抑制治疗的患者皮肤癌的发生频率和类型。
对 2002 年 1 月至 2005 年 10 月期间首次在皮肤科门诊就诊的 243 名肾移植患者的数据进行了多变量逻辑回归分析。
我们发现患有基底细胞癌(BCC)/鳞状细胞癌(SCC)比为 1:7 的肾移植患者发生光化性角化病(AK)和 SCC 的风险增加。老年患者更频繁地发生 AK(优势比[OR]1.11,95%置信区间[CI]1.06-1.15;p<0.0001)和 SCC(OR 1.14,CI 1.07-1.22;p<0.0001)比年轻患者。男性比女性更频繁地发生 AK(OR 0.19,CI 0.08-0.45;p=0.0002)和 SCC(OR 0.25,CI 0.07-0.89;p=0.0332)。免疫抑制治疗的持续时间与 AK 的数量显著相关(OR 1.15,CI 1.08-1.24;p<0.0001)和 SCC(OR 1.16,CI 1.05-1.28;p=0.0025),皮肤白皙的患者发生 AK(OR 0.31,CI 0.14-1.24;p<0.0001)和 SCC(OR 0.11,CI 0.02-0.52;p=0.0054)的风险更高比深色皮肤的患者。我们无法确定任何特定的免疫抑制药物是 AK 或非黑色素瘤皮肤癌(NMSC)的特定危险因素。
肾移植人群皮肤癌发病率增加。皮肤癌的主要危险因素是皮肤白皙和免疫抑制治疗时间长。需要进行随访计划以早期发现皮肤癌和癌前病变。预防策略应包括专科皮肤科监测和自我检查。